ventricular arrhythmia ventricular tachycardia
Conditions
Interventions
A single fraction of 25 Gy will be given to the VT substrate. The VT substrate
will be defined on an individual patient basis by a clinical cardiac
electrophysiologist by combining different (imagin
Sponsors
Universitair Medisch Centrum Utrecht
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: medication and ablation therapy refractory ventricular arrhythmia
Exclusion criteria
Exclusion criteria: extreme arrhythmia substrate: polymorphic VT/VF, >3 distinct clinical VT morphologies, >5 distinct induced VT morphologies during testing
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Acceptable acute toxicity defined by CTCAE v5.0. The incidence of serious adverse events (SAEs, defined as >= grade 3) should be | — |
Secondary
| Measure | Time frame |
|---|---|
| To demonstrate the efficacy of STAR as defined by the reduction in VT burden (number of ICD interventions and/or ATP, changes in antiarrhythmic medication), and improvement in quality of life (PROM questionnaires). The reduction in VT burden should be >= 50% after treatment compared to the 6 month period prior to STAR. To record (potential) late treatment related toxicity after STAR. | — |
Countries
Netherlands
Outcome results
None listed